Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device

Mohammad Qasaimeh, Yichao C. Wu, Suman Bose, Anoop Menachery, Srikanth Talluri, Gabriel Gonzalez, Mariateresa Fulciniti, Jeffrey M. Karp, Rao H. Prabhala, Rohit Karnik

Research output: Contribution to journalArticle

Abstract

The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.

Original languageEnglish (US)
Article number45681
JournalScientific Reports
Volume7
DOIs
StatePublished - Apr 4 2017

Fingerprint

Lab-On-A-Chip Devices
Plasma Cells
Multiple Myeloma
Antibodies
Microfluidics
Bone Marrow
Syndecan-1
Equipment and Supplies
Blood Donors
Immunoglobulins
Flow Cytometry
Cell Count
Fluorescence

ASJC Scopus subject areas

  • General

Cite this

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. / Qasaimeh, Mohammad; Wu, Yichao C.; Bose, Suman; Menachery, Anoop; Talluri, Srikanth; Gonzalez, Gabriel; Fulciniti, Mariateresa; Karp, Jeffrey M.; Prabhala, Rao H.; Karnik, Rohit.

In: Scientific Reports, Vol. 7, 45681, 04.04.2017.

Research output: Contribution to journalArticle

Qasaimeh, M, Wu, YC, Bose, S, Menachery, A, Talluri, S, Gonzalez, G, Fulciniti, M, Karp, JM, Prabhala, RH & Karnik, R 2017, 'Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device', Scientific Reports, vol. 7, 45681. https://doi.org/10.1038/srep45681
Qasaimeh, Mohammad ; Wu, Yichao C. ; Bose, Suman ; Menachery, Anoop ; Talluri, Srikanth ; Gonzalez, Gabriel ; Fulciniti, Mariateresa ; Karp, Jeffrey M. ; Prabhala, Rao H. ; Karnik, Rohit. / Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. In: Scientific Reports. 2017 ; Vol. 7.
@article{b96d347b8ee449b4b115ae1b56ede112,
title = "Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device",
abstract = "The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70{\%}, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful {\^a} € liquid biopsy' that may complement or partially replace bone marrow aspiration.",
author = "Mohammad Qasaimeh and Wu, {Yichao C.} and Suman Bose and Anoop Menachery and Srikanth Talluri and Gabriel Gonzalez and Mariateresa Fulciniti and Karp, {Jeffrey M.} and Prabhala, {Rao H.} and Rohit Karnik",
year = "2017",
month = "4",
day = "4",
doi = "10.1038/srep45681",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device

AU - Qasaimeh, Mohammad

AU - Wu, Yichao C.

AU - Bose, Suman

AU - Menachery, Anoop

AU - Talluri, Srikanth

AU - Gonzalez, Gabriel

AU - Fulciniti, Mariateresa

AU - Karp, Jeffrey M.

AU - Prabhala, Rao H.

AU - Karnik, Rohit

PY - 2017/4/4

Y1 - 2017/4/4

N2 - The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.

AB - The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ∼40-70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2-5 CD138 + cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20-24 CD138 + cells/mL), and yet higher numbers in MM patients exhibiting disease (45-184 CD138 + cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful â € liquid biopsy' that may complement or partially replace bone marrow aspiration.

UR - http://www.scopus.com/inward/record.url?scp=85016930527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016930527&partnerID=8YFLogxK

U2 - 10.1038/srep45681

DO - 10.1038/srep45681

M3 - Article

C2 - 28374831

AN - SCOPUS:85016930527

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 45681

ER -